• Mashup Score: 0

    Tailored management for high-risk locoregional disease, with more effective immunotherapy combinations are key areas

    Tweet Tweets with this article
    • #ESMO23:After recent advancements in #nasopharingeal #CancerManagement, due to #immunotherapy and an effective #biomarker, what’s next for #NPC? Anthony Chan: treating patients w/ post-treatment residual #EBV DNA is an issue #ESMODailyReporter 👉 https://t.co/xNMCMhmQk6 https://t.co/6u2uzcmCwL

  • Mashup Score: 0
    Steering Committee - 6 month(s) ago

    SELECT DISEASE STATE TO EXPLORE To bring key stakeholders (HCPs, pharmaceutical and biotech companies, associations and advocacy groups) together for the common purpose of providing accurate and relevant information to the broader oncology community about the importance of testing and biomarker identification, and how to utilize biomarker status to inform treatment decisions. To emphasize the importance of biomarker testing, comprehensive genomic profiling, and identification of actionable targets across

    Tweet Tweets with this article
    • Learn about the importance of #biomarker testing in #NSCLC through the OncLive Biomarker Consortium. Learn more https://t.co/e9DfwzMfeb https://t.co/Likucqa8Rj

  • Mashup Score: 0

    Background An increased number of resources are allocated on cancer biomarker discovery, but very few of these biomarkers are clinically adopted. To bridge the gap between Biomarker discovery and clinical use, we aim to generate the Biomarker Toolkit, a tool designed to identify clinically promising biomarkers and promote successful biomarker translation. Methods All features associated with a clinically useful biomarker were identified using mixed-methodology, including systematic literature search, semi-structured interviews, and an online two-stage Delphi-Survey. Validation of the checklist was achieved by independent systematic literature searches using keywords/subheadings related to clinically and non-clinically utilised breast and colorectal cancer biomarkers. Composite aggregated scores were generated for each selected publication based on the presence/absence of an attribute listed in the Biomarker Toolkit checklist. Results Systematic literature search identified 129 attribut

    Tweet Tweets with this article
    • Saava et al develop the #BiomarkerToolkit — an evidence-based guideline to predict cancer biomarker success and guide development. Rationale, clinical and analytical validity are important for #biomarker success #oncotwitter @Oesophagusuk https://t.co/XwWWut5Onn https://t.co/XNo42eQRr0

  • Mashup Score: 1

    A new report published by Knudsen et al in PLOS ONE focused on the clinical validation of a drug response predictor (DRP) biomarker algorithm for dovitinib, a receptor tyrosine kinase inhibitor of VEGFR1–3, PDGFR, FGFR1/3, c-KIT, FLT3, and topoisomerase 1 and 2. Data showed that the DRP-dovitinib tool was able to identify a subgroup of patients with advanced renal cell carcinoma (RCC) with improved clinical benefit from dovitinib treatment compared with unselected patients. “This is the first validated

    Tweet Tweets with this article
    • Newly Published Data on a Response Biomarker for Dovitinib in Patients With RCC https://t.co/bqG1scifYw #kcsm #kidneycancer #RCC #oncology #biomarker